However, it should be noted that BRAF/MEKi combination therapies are the standard of care for BRAF V600-mutant metastatic melanoma, which accounts for approximately 40–50% of all melanoma cases [2,27]. The gene discussed is BRAF; the disease is metastatic melanoma.